Reportlinker Adds Global ADHD Therapeutics Industry

Jun 24, 2010, 21:11 ET from Reportlinker

NEW YORK, June 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global ADHD Therapeutics Industry

http://www.reportlinker.com/p0209266/Global-ADHD-Therapeutics-Industry.html

This report analyzes the worldwide markets for ADHD Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US and Rest of World. Annual estimates and forecasts are provided for each region for the period of 2006 through 2015. The report profiles 27 companies including many key and niche players such as Eli Lilly & Company, Johnson & Johnson, Janssen-Cilag, Novartis AG, Shire Plc, UCB S.A., Companies with Drugs in Pipeline for ADHD: Abbott Laboratories, Inc., Cortex Pharmaceuticals, Inc., KemPharm, Inc., and NeuroSearch A/S. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ADHD THERAPEUTICS MCP-6195

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Prelude II-1

Lack of Awareness - A Major Impediment II-1

Adult ADHD - A Growing Market Opportunity II-2

Table 1: Market Share of ADHD Prescriptions by Age Category:

Children, Adolescents and Adults (includes corresponding

Graph/Chart) II-2

Unfulfilled Needs Provide Impetus to Develop New Molecules II-3

Safety Concerns Foster Research in Non Stimulant Segment II-3

Presence of Co-morbidities with ADHD Creates Opportunities for

Combination Therapies II-3

Introduction of Generics Shakes Market II-3

Patent Expiries of Major Drugs in the ADHD Market II-4

2. COMPETITIVE SCENARIO II-5

Table 2: Leading Brands in the Global ADHD Market by

Prescription Share (2008) (includes corresponding Graph/Chart) II-5

Shire Leads the Way II-5

J&J's Concerta - Leading Drug for ADHD by Default II-6

Eli Lilly's Strattera - Creating a Niche II-6

Novartis Retains Market Share II-7

Pipeline Drugs II-7

3. THE ADHD CONUNDRUM II-8

ADHD - A Disorder or Marketing Gimmick of Pharmaceutical

Companies? II-8

Lack of Clear Guidelines and Criteria for Adult Diagnosis

Hampers Market II-8

Differences in Diagnostic Criteria in Europe and US II-9

Hiccups in the Way II-9

ADHD in Women II-9

4. ADHD - AN INSIGHT II-11

Attention Deficit Hyperactivity Disorder (ADHD) - Introduction II-11

Brief History of the Disorder II-11

Common Co-Occurring Disorders With ADHD II-12

Consequences of ADHD II-12

What Leads to ADHD? II-12

Study Reveals Deficits in Protein Levels in Brain's Reward/

Motivation System II-12

ADHD Symptoms II-13

DSM IV Criteria for Diagnosis of ADHD II-13

DSM IV Criteria for Inattention and Hyperactivity/ Impulsivity II-13

Types of ADHD II-14

Treating ADHD II-14

Stimulants II-14

Non-stimulants II-14

Others II-14

5. REVIEW OF SELECT DRUGS II-16

ADHD Drugs - Background II-16

Brand Review II-16

Ritalin LA II-16

Focalin II-16

Table 3: Global Revenues of Novartis' ADHD Drugs - Ritalin/

Focalin (2008-2009) (in US$ million) II-16

Concerta II-17

Table 4: Global Revenues of Concerta (2006-2009) (includes

corresponding Graph/Chart) II-17

Strattera II-17

Table 5: Global Revenues of Strattera (2006-2009) (in US$

million) (includes corresponding Graph/Chart) II-17

Metadate CD II-18

Table 6: Global Revenues of Metadate CD/Equasym (2007-2008)

(in €Million) II-18

Adderall XR II-18

Table 7: Global Revenues of Adderall XR (2006-2009) (in US$

million) (includes corresponding Graph/Chart) II-18

Daytrana II-19

Table 8: Global Revenues of Daytrana (2006-2009) (in US$

million) (includes corresponding Graph/Chart) II-19

Vyvanse II-19

Table 9: Global Revenues of Vyvanse (2007-2009) (in US$

million) (includes corresponding Graph/Chart) II-20

Intuniv II-20

6. RESEARCH PIPELINE II-22

Supernus Pharmaceuticals' SPN 810 Proves Successful in Phase

IIa Clinical Trials II-23

KemPharm Announces Completion of Phase I Trials of KP106 II-23

Shire Announces Results of Phase IIIb Clinical Trials of

Daytrana® in Adolescents II-23

Addrenex and Sciele Pharma Submit sNDA for Clonicel for ADHD

Treatment II-24

Targacept Collaborates with AstraZeneca for AZD3480 Clinical

Trials II-24

Neptune Technologies Announces Positive Reports on Pre-

Clinical Trials of Medical Food Candidate for Treatment of

ADHD II-24

NeuroSearch Completes Phase II Studies on Efficacy and

Security of ABT-894 in Adults with ADHD II-24

Abbott Announces Positive Results From Phase II Studies of a

Novel Approach of Treating ADHD II-25

7. PRODUCT LAUNCHES/INTRODUCTIONS II-26

Shire Unveils First Prodrug Therapy for ADHD in Canadian Market II-26

Teva Launches First Authorized Generic Version of Adderall XR®

Capsules II-26

Shire Introduces INTUNIV™ II-26

Eli Lilly Japan Introduces Strattera in the Country II-26

8. RECENT INDUSTRY ACTIVITY II-27

Avacta Group Acquires TheraGenetics II-27

AstraZeneca Grants Interim Payment to Targacept II-27

Addrenex Pharmaceuticals Inks Agreement with Dream Pharma II-27

Durect Signs Agreement with Orient Pharma II-27

Hisamitsu Pharmaceutical Acquires Noven Pharmaceutical II-28

Shire Receives FDA Approval for INTUNIV Tablets II-28

Shire Pharmaceuticals and GSK Sign a Co-Promotion Deal for

Vyvanse II-28

Shire Pharmaceuticals Establishes Office in Tokyo II-28

Shire and UCB Enter into Agreement II-29

Shire Retains Exclusivity for Vyvanse II-29

Shire Settles Litigation with Sandoz for Generic Adderall II-29

Sciele Pharma to Takeover Addrenex Pharmaceuticals II-29

Auriga Laboratories Receives Approval from FDA for LiquaddTM II-30

Concerta Extended Release Tablets Receive US FDA Approval for

Use in Adult Treatment II-30

Eurand Enters into Settlement with UCB II-30

Paladin Labs Secures Dexedrine's Distribution Rights from

GlaxoSmithKline II-30

Shire Receives Approval from FDA for Use of Vyvanse in Adults II-31

Strattera Receives FDA Approval for Maintenance of ADHD in

Children & Adolescents II-31

The Dore Group Providing Alternate ADHD Treatment to Drugs

Goes Into Liquidation II-31

Shire Takes Over New River Pharmaceuticals to Gain Full

Control Over Vyvanse™ II-31

9. FOCUS ON SELECT PLAYERS II-32

Eli Lilly & Company (USA) II-32

Johnson & Johnson (USA) II-32

Janssen-Cilag (Switzerland) II-32

Novartis AG (Switzerland) II-33

Shire Plc (The UK) II-33

UCB S.A. (Belgium) II-34

Companies with Drugs in Pipeline for ADHD II-34

Abbott Laboratories, Inc. (USA) II-34

Cortex Pharmaceuticals, Inc. (US) II-34

KemPharm, Inc. (USA) II-35

NeuroSearch A/S (Denmark) II-35

10. GLOBAL MARKET PERSPECTIVE II-36

Table 10: World Recent Past, Current & Future Analysis for

Attention Deficit Hyperactivity Disorder (ADHD) by Geographic

Region - US and Rest of World Markets Independently Analyzed

with Annual Revenues in US$ Million for Years 2006 through

2015 (includes corresponding Graph/Chart) II-36

Table 11: World 10 -Year Perspective for Attention Deficit

Hyperactivity Disorder (ADHD) Market by Geographic Region -

Percentage Breakdown of Revenues for US and Rest of World

Markets for Years 2006, 2009 and 2015 II-36

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Current and Future Analysis III-1

ADHD Epidemic in the US ! III-1

Table 12: Prevalence Rate of ADHD in Different Backgrounds

According to Age, Ethnicity, Gender and Family Structure in

the US in 2007 III-1

Causes for Widespread ADHD Diagnosis and Treatment in the US III-2

ADHD Drugs Combat Safety Concerns III-2

Market Exhibits Greater Potential III-2

Table 13: Percentage Share of ADHD Prescriptions in US by

Patient Category - Children, Adolescents and Adults (2002

and 2007) (includes corresponding Graph/Chart) III-2

Lack of Clear Guidelines and Criteria for Adult Diagnosis

Hampers Market III-3

Cyclical Nature of ADHD Market III-3

Competitive Scenario III-3

Table 14: Leading Players and Drug Brands in the US ADHD

Market (2007, 2008) : Percentage Breakdown of Prescriptions

for Shire, McNeil Janssen, Eli Lilly, Novartis, Celltech,

Pharmaceuticals / UCB, and Others (includes corresponding

Graph/Chart) III-4

Product Launches III-4

Strategic Corporate Developments III-5

Select Players III-8

B.Market Analytics III-10

Table 15: US Recent Past, Current & Future Analysis for

Sales Force Automation (SFA) Market Independently Analyzed

with Annual Revenue Figures in US$ Million for Years 2006

through 2015 (includes corresponding Graph/Chart) III-10

2. REST OF WORLD III-11

A.Market Analysis III-11

Current and Future Analysis III-11

Review of Select Markets III-11

Canada III-11

Concerta Leads the Market III-11

Table 16: Leading Drug Brands in the Canadian ADHD Market

(2008): Percentage Share Breakdown of Revenues for

Concerta, Adderall, Dexedrine, Generics, and Others

(includes corresponding Graph/Chart) III-11

Europe III-12

Germany III-12

Table 17: Prevalence Rates of ADHD in Germany in Terms of

Gender, Age and Socioeconomic Status Reimbursement Policy III-12

The United Kingdom III-12

Australia III-13

Product Launches III-13

Strategic Corporate Developments III-13

Select Players III-16

B.Market Analytics III-18

Table 18: Rest of World Recent Past, Current & Future

Analysis for Attention Deficit Hyperactivity Disorder (ADHD)

Drugs Analyzed with Annual Revenues in US$ Million for Years

2006 through 2015 (includes corresponding Graph/Chart) III-18

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 27 (including Divisions/Subsidiaries - 33)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 20

Japan 2

Europe 9

Germany 1

The United Kingdom 4

Rest of Europe 4

Asia-Pacific (Excluding Japan) 1

Middle-East 1

------------------------------------------

To order this report:

Drug and Medication Industry: Global ADHD Therapeutics Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!


Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626




SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com